ClinicalTrials.gg
RecruitingNCT07660055Updated Nov 3, 2026

Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors

A Phase 1 interventional study of [68Ga]Ga-DWJ155 and [177Lu]Lu-DWJ155 in Breast Cancer, Non-small Cell Lung Cancer (NSCLC) and Gastric/Gastroesophageal Junction (GEJ) Cancer, sponsored by Novartis Pharmaceuticals. Recruiting at 6 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Nov 3, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
156
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 199 studies in Breast Neoplasms by Novartis — 16 open to participants now, 30 under way, 4 of them phase 3. Breast Neoplasms · Novartis.

Planned enrollment
67th of 155
156 · median 104
Started
2026
with 9 others
Phase 1
40 of 199
6 open now
Primary completion
2032-05
later than 27 of 29 live
Registered
195th of 199
by date

Among the 199 studies in Breast Neoplasms by Novartis, this one is the 67th largest by planned enrollment of the 155 interventional ones that give a count, is one of 10 that started in 2026, is one of 40 in phase 1, reaches primary completion later than 27 of the 29 other live ones, and was the 195th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

16 of the 199 studies in Breast Neoplasms by Novartis are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 199 studies in Breast Neoplasms by Novartis, or all of them as a file.
02

Study summary

The purpose of this phase I study is to evaluate the safety, tolerability, dosimetry, and preliminary anti-tumor activity of [177Lu]Lu-DWJ155 and the safety and imaging properties of [68Ga]Ga-DWJ155 in patients with histologically or cytologically confirmed advanced HER2+, HR+/HER2-negative, or triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), HER2-3+ or 2+ (ISH positive or negative) gastric/gastroesophageal junction (GEJ) cancer, and bladder cancer.

Read the detailed description

The study will be done in two parts. The first part is called "escalation" and the second part is called "expansion". In both parts of the study, patients will initially be imaged with a [68Ga]Ga-DWJ155 positron emission tomography (PET)/computed tomography (CT) or PET/magnetic resonance imaging (MRI) scan. In the escalation part, different doses of [177Lu]Lu-DWJ155 will then be tested to identify recommended dose(s) (RD(s)) for further evaluation. The expansion part of the study will examine the safety and preliminary efficacy of [177Lu]Lu-DWJ155 at the RD(s) determined during the escalation part.

In both parts, there will be a safety follow-up period after the last [177Lu]Lu-DWJ155 administration.

03

Conditions studied

  • Breast Cancer
  • Non-small Cell Lung Cancer (NSCLC)
  • Gastric/Gastroesophageal Junction (GEJ) Cancer
  • Bladder Cancer

Keywords

  • Breast cancer
  • Non-small cell lung cancer (NSCLC)
  • Bladder cancer
  • Gastric/gastroesophageal junction (GEJ)
  • Radioligand therapy (RLT)
  • [177Lu]Lu-DWJ155
  • [68Ga]Ga-DWJ155
  • Human Epidermal Growth Factor Receptor 2 (HER2)
  • FML539
  • FKL480
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients age ≥ 18 years.
  • Patients with one of the following or cytologically confirmed and documented who have progressed on or been intolerant to standard of care therapy, and are not considered appropriate for any standard therapy with proven benefit, in the investigator's judgment:
  • Dose Escalation:

    • Advanced + breast cancer with disease progression after at least two in the advanced setting
    • Advanced HR+/HER2-low breast cancer with disease progression after prior therapy in the advanced setting
    • Advanced NSCLC without actionable genetic alterations (AGAs) with disease progression after prior therapy in the advanced setting
    • Advanced NSCLC with AGAs who have received prior treatment
    • as determined by version 1.1.
  • Dose Expansion:

    • Advanced HER2+ breast cancer with disease progression after at least two prior lines of systemic therapy in the advanced setting
    • Advanced HR+/HER2-low breast cancer with disease progression after prior therapy in the advanced setting
    • Advanced HR+/HER2 0 breast cancer with disease progression after prior therapy in the advanced setting
    • Advanced HR-/HER2-low breast cancer with disease progression after prior therapy in the advanced setting
    • Advanced HR-/HER2 0 breast cancer with disease progression after prior therapy in the advanced setting
    • Advanced NSCLC with AGAs, who have received prior treatment
    • Advanced NSCLC without known AGAs who have received prior treatment.
    • Advanced gastric/GEJ cancer with HER2 IHC 3+ or 2+ (ISH + or -), following disease progression after prior therapy in the advanced setting
    • Advanced bladder cancer following disease progression after prior therapy in the advanced setting
    • Measurable disease as determined by RECIST version 1.1.

Exclusion criteria

Exclusion Criteria:

  • Out-of-range laboratory values defined as:

    • \< 60 mL/min (calculated using 2021 formula, or measured)
    • Total > 1.5 x (except for patients with Gilbert's syndrome who are excluded if total bilirubin >3.0 x ULN) or direct bilirubin > 1.5 x ULN
    • (ALT) > 3 x ULN, except for patients with tumor involvement of the liver who are excluded if ALT > 5 x ULN
    • Aspartate aminotransferase (AST) > 3 x ULN, except for patients with tumor involvement of the liver who are excluded if AST > 5 x ULN
    • Lipase > 1.5 x ULN
    • (ANC) \< 1.5 x 109/L
    • \< 9 g/dL
    • count \< 100 x 109/L
  • Initiation of hematopoietic colony stimulating factors, thrombopoietin mimetics, or erythroid stimulating agents initiated ≤ 2 weeks prior to imaging agent administration.
  • Use of transfusion support ≤4 weeks prior to imaging agent administration.
  • Impaired cardiac function or cardiac disease.
  • Unmanageable urinary tract obstruction or urinary incontinence.
  • Any serious uncontrolled infection (acute or chronic).
  • Pregnant or breastfeeding women.
  • Treatment with any of the following anti-cancer therapies prior to imaging agent administration within the stated timeframes:

    • Prior treatment with any therapeutic radiopharmaceutical
    • \< 10 half-lives for any imaging radiopharmaceutical
    • ≤ 4 weeks for external beam radiation therapy (EBRT) or brachytherapy
    • ≤ 6 months for lung-directed external beam radiotherapy
  • Patients with non-tumor uptake of [68Ga]Ga-DWJ155 in tissues or organs that, in the opinion of the investigator, increases the risk associated with [177Lu]Lu-DWJ155 treatment.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
156 participants (estimated)

Study arms

  • Experimental
    Dose Escalation

    Patients will receive \[68Ga\]Ga-DWJ155 and, if eligible, \[177Lu\]Lu-DWJ155. In this part, multiple dose levels of \[177Lu\]Lu-DWJ155 will be evaluated.

    Diagnostic Test: [68Ga]Ga-DWJ155 · Drug: [177Lu]Lu-DWJ155

  • Experimental
    Dose Expansion

    Patients will receive \[68Ga\]Ga-DWJ155 and, if eligible, \[177Lu\]Lu-DWJ155 at the recommended dose established during the dose escalation part.

    Diagnostic Test: [68Ga]Ga-DWJ155 · Drug: [177Lu]Lu-DWJ155

Interventions

  • Diagnostic test[68Ga]Ga-DWJ155

    Radioligand imaging agent

    Also known as: FKL480

  • Radioligand therapy

    Also known as: FML539

06

What researchers measure

Primary outcomes

  1. Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) of [177Lu]Lu-DWJ155

    Incidence and severity of AEs and SAEs, including changes in laboratory values, vital signs, echocardiograms (ECGs), and imaging assessments qualifying and reported as AEs.

    Time frame: Up to approximately 53 months

  2. Incidence of dose-limiting toxicities (DLTs) of [177Lu]Lu-DWJ155

    A DLT is defined as an adverse event or abnormal laboratory value of Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 3 assessed as unrelated to disease, disease progression, inter-current illness/injury or concomitant medications that occurs within the first treatment cycle. Other clinically significant toxicities may be considered to be DLTs, even if not CTCAE grade 3 or higher.

    Time frame: Up to 6 weeks

  3. Frequency of dose interruptions and reductions [177Lu]Lu-DWJ155

    Number of participants with dose interruptions and/or reductions to assess the tolerability.

    Time frame: 11 months

  4. Dose intensity [177Lu]Lu-DWJ155

    Dose intensity defined as the ratio of actual cumulative dose received and actual duration of exposure

    Time frame: 11 months

Secondary outcomes

  1. Overall Response Rate (ORR) per RECIST v1.1

    ORR is defined as the proportion of patients with a best overall response (BOR) of complete response (CR) or partial response (PR) as per local review and according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).

    Time frame: Up to approximately 53 months

  2. Disease Control Rate (DCR) per RECIST v1.1

    DCR is defined as the proportion of patients with a BOR of CR, PR, or stable disease (SD) as per local review and according to RECIST v1.1.

    Time frame: Up to approximately 53 months

  3. Duration of Response (DOR) per RECIST v1.1

    DOR is the time between the first documented response (CR or PR) and the date of progression as per local review and according to RECIST v1.1, or death due to any cause.

    Time frame: Up to approximately 53 months

  4. Progression-Free Survival (PFS) per RECIST v1.1

    PFS is defined as the time from the date of start of treatment to the date of the first documented progression as per local review and according to RECIST v1.1 or death due to any cause.

    Time frame: Up to approximately 53 months

  5. Area under the concentration-time curve (AUC) of [177Lu]Lu-DWJ155

    The pharmacokinetic (PK) analysis will be performed based on decay-corrected blood radioactivity concentration data converted to mass units. AUC will be determined by non-compartmental methods.

    Time frame: From pre-dose up to 168 hours after the end of the infusion on Day 1

  6. Systemic clearance (CL) of [177Lu]Lu-DWJ155

    The PK analysis will be performed based on decay-corrected blood radioactivity concentration data converted to mass units. CL will be determined by non-compartmental methods.

    Time frame: From pre-dose up to 168 hours after the end of the infusion on Day 1

  7. Maximum observed concentration (Cmax) of [177Lu]Lu-DWJ155

    The PK analysis will be performed based on decay-corrected blood radioactivity concentration data converted to mass units. Cmax will be determined by non-compartmental methods.

    Time frame: From pre-dose up to 168 hours after the end of the infusion on Day 1

  8. Volume of distribution during the terminal phase (Vz) of [177Lu]Lu-DWJ155

    The PK analysis will be performed based on decay-corrected blood radioactivity concentration data converted to mass units. Vz will be determined by non-compartmental methods.

    Time frame: From pre-dose up to 168 hours after the end of the infusion on Day 1

  9. Terminal half-life (T1/2) of [177Lu]Lu-DWJ155

    The PK analysis will be performed based on decay-corrected blood radioactivity concentration data converted to mass units. T1/2 will be determined by non-compartmental methods.

    Time frame: From pre-dose up to 168 hours after the end of the infusion on Day 1

  10. Urinary excretion of [177Lu]Lu-DWJ155

    The PK analysis will be performed based on decay-corrected urine radioactivity concentration data converted to mass units. Urinary excretion will be derived based on the percentage of injected dose excreted in urine in each collection interval and overall.

    Time frame: From pre-dose up to 72 hours after the end of the infusion on Day 1

  11. Renal clearance (CLr) of [177Lu]Lu-DWJ155

    The PK analysis will be performed based on decay-corrected blood and urine radioactivity concentration data converted to mass units. CLr will be determined by non-compartmental methods.

    Time frame: From pre-dose up to 72 hours after the end of the infusion on Day 1

  12. Absorbed radiation dose in selected organs, tumor lesions and total body of [177Lu]Lu-DWJ155

    Single Photon Emission Computed Tomography/Computed Tomography (SPECT/CT) images will be acquired to assess total body, organ and tumor lesion dosimetry.

    Time frame: Up to 168 hours after the end of the infusion on Day 1

  13. Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) of [68Ga]Ga-DWJ155:

    Incidence and severity of AEs and SAEs, including changes in laboratory values, vital signs, echocardiograms (ECGs), and cardiac imaging qualifying and reported as AEs.

    Time frame: Up to 3 days

  14. Standard uptake values (SUVs) in normal tissues and selected tumor lesions of [68Ga]Ga-DWJ155

    68Ga-DWJ155 positron emission tomography/computed tomography (PET/CT) or positron emission tomography/magnetic resonance imaging (PET/MRI) imaging assessments will be performed to derive SUVs in normal tissues and selected tumor lesions.

    Time frame: Up to approximately 1.5 hours after the end of infusion

07

Study locations

6 of 6 sites recruiting
  • Nebraska Cancer Specialists
    Omaha, Nebraska 68130, United States
    Recruiting
  • Memorial Sloan Kettering Cancer Ctr
    New York, New York 10065, United States
    Recruiting
    • Jamie Walters · Contactwaltersj@mskcc.org · +1 646 227 2173
    • Komal Jhaveri · Principal investigator
  • Novartis Investigative Site
    Darlinghurst, New South Wales 2010, Australia
    Recruiting
  • Novartis Investigative Site
    Montreal, Quebec H2X 0A9, Canada
    Recruiting
  • Novartis Investigative Site
    Montreal, Quebec H4A 3J1, Canada
    Recruiting
  • Novartis Investigative Site
    Kashiwa, Chiba 2778577, Japan
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for May 2032, 71 months after the start.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's planned 71 months is above that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2026
First posted
Jun 22, 2026
StartActual
Jun 16, 2026
Primary completionEst.
May 24, 2032
CompletionEst.
May 24, 2032
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Memorial Sloan Kettering Cancer Ctr · New York, United States
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    1 site added
    Show site
    • Memorial Sloan Kettering Cancer Ctr · New York, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07660055
Responsible party
Sponsor
First posted
Jun 22, 2026
Start date
Jun 16, 2026
Primary completion
May 24, 2032 (estimated)
Completion
May 24, 2032 (estimated)
Last update
Nov 3, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
1-888-669-6682
Novartis Pharmaceuticals
Contact
+41613241111

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lutetium-177

Start the discussion